TY  - CONF

T1  - Dupilumab treatment is associated with reductions in serum immunoglobulin E and thymus and activation-regulated chemokine levels in children aged 6 to 11 years with severe atopic dermatitis

JO  - CLINICAL AND EXPERIMENTAL ALLERGY

PY  - 2022/01/01

AU  - Cork MJ

AU  - Wollenberg A

AU  - Siegfried E

AU  - Chen Z

AU  - Levit NA

AU  - Rodriguez Marco A

ED  - 

VL  - 52

IS  - 8

SP  - 1059

EP  - 1059

Y2  - 2024/12/22

ER  -